Wall Street Experts
ver. ZuMIgo(08/25)
Fulcrum Therapeutics, Inc.
Rachunek Zysków i Strat
Przychody TTM (mln): 81
EBIT TTM (mln): -25
index |
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
Rok finansowy |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Przychód (mln) |
0 |
0 |
0 |
9 |
19 |
6 |
3 |
80 |
Przychód Δ r/r |
0.0% |
0.0% |
0.0% |
inf% |
117.2% |
-66.9% |
-55.8% |
2752.0% |
Marża brutto |
0.0% |
0.0% |
-inf% |
73.0% |
86.9% |
61.9% |
22.6% |
100.0% |
EBIT (mln) |
-23 |
-33 |
-84 |
-72 |
-81 |
-113 |
-111 |
-22 |
EBIT Δ r/r |
0.0% |
45.7% |
151.4% |
-15.0% |
13.2% |
38.9% |
-1.7% |
-80.2% |
EBIT (%) |
0.0% |
0.0% |
0.0% |
-811.6% |
-423.0% |
-1774.9% |
-3945.2% |
-27.4% |
Koszty finansowe (mln) |
0 |
0 |
0 |
0 |
0 |
-3 |
0 |
0 |
EBITDA (mln) |
-22 |
-32 |
-84 |
-72 |
-81 |
-112 |
-108 |
-18 |
EBITDA(%) |
0.0% |
0.0% |
0.0% |
-811.6% |
-423.0% |
-1761.4% |
-3867.8% |
-22.8% |
Podatek (mln) |
-0 |
1 |
-4 |
-2 |
-3 |
-4 |
0 |
0 |
Zysk Netto (mln) |
-23 |
-33 |
-79 |
-68 |
-78 |
-106 |
-97 |
-10 |
Zysk netto Δ r/r |
0.0% |
41.9% |
142.8% |
-13.5% |
14.5% |
34.8% |
-7.8% |
-90.0% |
Zysk netto (%) |
0.0% |
0.0% |
0.0% |
-775.7% |
-408.8% |
-1665.4% |
-3470.1% |
-12.2% |
EPS |
-2.1 |
-1.92 |
-7.16 |
-2.7 |
-2.22 |
-2.35 |
-1.59 |
-0.17 |
EPS (rozwodnione) |
-2.1 |
-1.92 |
-7.16 |
-2.7 |
-2.22 |
-2.35 |
-1.59 |
-0.17 |
Ilośc akcji (mln) |
11 |
17 |
11 |
25 |
35 |
45 |
61 |
58 |
Ważona ilośc akcji (mln) |
11 |
17 |
11 |
25 |
35 |
45 |
61 |
58 |
Waluta |
USD |
USD |
USD |
USD |
USD |
USD |
USD |
USD |